Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Total Current Liabilities (2019 - 2025)

Silence Therapeutics' Total Current Liabilities history spans 7 years, with the latest figure at $13.6 million for Q4 2025.

  • For Q4 2025, Total Current Liabilities fell 19.08% year-over-year to $13.6 million; the TTM value through Dec 2025 reached $13.6 million, down 19.08%, while the annual FY2025 figure was $13.6 million, 19.08% down from the prior year.
  • Total Current Liabilities for Q4 2025 was $13.6 million at Silence Therapeutics, down from $17.4 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $25.7 million in Q4 2022 and bottomed at $13.6 million in Q4 2025.
  • The 5-year median for Total Current Liabilities is $18.3 million (2025), against an average of $18.8 million.
  • The largest annual shift saw Total Current Liabilities crashed 39.46% in 2021 before it increased 25.89% in 2022.
  • A 5-year view of Total Current Liabilities shows it stood at $20.4 million in 2021, then increased by 25.89% to $25.7 million in 2022, then decreased by 14.31% to $22.1 million in 2023, then fell by 23.72% to $16.8 million in 2024, then decreased by 19.08% to $13.6 million in 2025.
  • Per Business Quant, the three most recent readings for SLN's Total Current Liabilities are $13.6 million (Q4 2025), $17.4 million (Q3 2025), and $14.8 million (Q2 2025).